Indegene Ltd

Indegene will hold a meeting of the Board of Directors of the Company on 28 April 2025.Powered by Capital Market - Live

Indegene, a digital-first life sciences commercialization company, today announced the launch of a new center in London. This aligns with the company's long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready. Indegene's Europe-based clients can now benefit from this center as a strategic hub for consulting and commercialization solutions and modernize their operations with an AI-first approach. The company is strengthening its existing employee base in the region, with skillsets spanning a wide range of areas - consulting, creative, data and analytics, engineering and customer experience. 'London is a vital healthcare, technology and business innovation hub, with a great talent pool - making it an important market for life sciences companies in the region', said Manish Gupta, Chairman and CEO, Indegene. 'With our new center, we are better positioned to dial up innovation and engagement with our clients here and help them holistically improve their commercialization processes with an AI-first approach and stay ahead of the curve.'Powered by Capital Market - Live

Indegene has been recognized as one of the standout winners of Deloitte Private's Enterprise Growth Awards 2025. The awards acknowledged Indegene's commitment to its purpose of enabling healthcare organizations to be future-ready, its robust corporate governance practices and sustained growth. Enterprise Growth Awards is a unique programme by Deloitte Private dedicated to celebrating businesses that have transformed local ambitions into national and global success stories. These awards showcase inspiring stories of businesses that have built lasting legacies while maintaining sustainable growth trajectories and aim to inspire the next generation of entrepreneurs. Powered by Capital Market - Live

Indegene has been recognized as one of the standout winners of Deloitte Private's Enterprise Growth Awards 2025. The awards acknowledged Indegene's commitment to its purpose of enabling healthcare organizations to be future-ready, its robust corporate governance practices and sustained growth. Enterprise Growth Awards is a unique programme by Deloitte Private dedicated to celebrating businesses that have transformed local ambitions into national and global success stories. These awards showcase inspiring stories of businesses that have built lasting legacies while maintaining sustainable growth trajectories and aim to inspire the next generation of entrepreneurs. Powered by Capital Market - Live

Indegene launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multiagent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domainfriendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM state-of-the-art improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement.  Powered by Capital Market - Live

Indegene announced the launch of a new entity in Spain. This move marks a key step in the company's ongoing strategic expansion in Europe and aligns with Indegene's commitment to helping life sciences companies accelerate AI-driven innovation and make their operations future-ready. Indegene's new Spain entity will serve as a key delivery hub for its Europe-based clients, helping them drive hyper-personalization and significantly elevate HCP and patient experience. The company is strengthening its already existing employee base in Spain, with capabilities in medical affairs, data and analytics, creative design, engineering, digital marketing and customer experience. Indegene already has a significant presence in Europe, with centers in the UK, Germany, Ireland and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. Indegene supports many leading life sciences clients in the region in various ways across the commercialization value chain. Powered by Capital Market - Live

Net profit of Indegene rose 11.03% to Rs 109.70 crore in the quarter ended December 2024 as against Rs 98.80 crore during the previous quarter ended December 2023. Sales rose 6.98% to Rs 720.40 crore in the quarter ended December 2024 as against Rs 673.40 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales720.40673.40 7 OPM %18.3022.11 - PBDT166.30149.90 11 PBT146.30132.30 11 NP109.7098.80 11 Powered by Capital Market - Live

Indegene will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live

Indegene has granted 88,021 RSUs to the eligible employees of the company under ESOP. Powered by Capital Market - Live

The said collaboration marks a significant milestone in advancing the efficiency and effectiveness of clinical trial operations globally. 'With a client base that includes the world's top 20 pharma companies, Indegene brings a strong track record of modernizing the industry with its deep domain expertise and life sciences-contextualized technology, spanning the entire product lifecycle from development to commercialization. Indegene's aim to expand its footprint in the clinical trial domain complements CliniOps' cutting-edge technologies and capabilities in this space,' it added. Together, CliniOps and Indegene aim to deliver a joint vision of accelerating clinical trial conduct by redefining industry standards. As part of this collaboration, Indegene will provide its expertise in patient recruitment and data services, leveraging CliniOps' Unified Platform, which ensures high data quality, brings speed, and streamlines data collection from various data sources. Ram Yeleswarapu, SVP, Enterprise Clinical Solutions, Indegene, said, 'This new partnership aligns with Indegene's strategy of leveraging data and technology across the entire clinical trial value chain, with a goal to enable faster, more efficient, and cost-effective clinical development.' Dr. Abhijit Barve, Advisor, CliniOps, and former Chief Medical Officer, Viatris, said, 'To lead the transformation of clinical trial operations into a more future-ready and efficient state, partnerships like the one between Indegene and CliniOps are critical. Sponsors are increasingly seeking partners with agile and integrated solutions that not only help unlock actionable patient insights but also accelerate recruitment, enhance data quality, and improve overall trial management.' Avik Pal, CliniOps' CEO, expressed enthusiasm for the collaboration, stating, 'This partnership is an exciting opportunity for CliniOps and Indegene to complement each other's strengths and ultimately deliver better therapeutic outcomes for patients.' Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. The company assists in drug development, clinical trials, regulatory submissions, pharmacovigilance, complaint management, and sales and marketing. The company's consolidated net profit increased 22.3% to Rs 91.70 crore on a 8% rise in revenue from operations to Rs 686.80 crore in Q2 FY25 over Q2 FY24. Shares of Indegene fell 0.54% to Rs 625.40 on the BSE.Powered by Capital Market - Live